about
Understanding the global epidemiology of pediatric critical illness: the power, pitfalls, and practicalities of point prevalence studiesSepsis-associated in-hospital cardiac arrest: Epidemiology, pathophysiology, and potential therapies.Pediatric Sepsis Biomarker Risk Model-II: Redefining the Pediatric Sepsis Biomarker Risk Model With Septic Shock Phenotype.Comparison of Pediatric Severe Sepsis Managed in U.S. and European ICUs.Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsDelayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis.Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals.Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.Differential expression of the nuclear-encoded mitochondrial transcriptome in pediatric septic shockThe temporal version of the pediatric sepsis biomarker risk model.Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypesDeveloping a clinically feasible personalized medicine approach to pediatric septic shockOutcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.Discordant identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study.Differential expression of the Nrf2-linked genes in pediatric septic shock.2016 Update for the Rogers' Textbook of Pediatric Intensive Care: Recognition and Initial Management of Shock.Comparison of Two Sepsis Recognition Methods in a Pediatric Emergency Department.A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury.Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology.Hyperferritinemic Sepsis: An Opportunity for Earlier Diagnosis and Intervention?Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model.Association of Delayed Antimicrobial Therapy with One-Year Mortality in Pediatric Sepsis.American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.Crystalloid Fluid Choice and Clinical Outcomes in Pediatric Sepsis: A Matched Retrospective Cohort Study.New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis: A Sepsis Phenotype With Higher Morbidity and Mortality.Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Acute Kidney Injury in Pediatric Severe Sepsis: An Independent Risk Factor for Death and New Disability.Protocolized Treatment Is Associated With Decreased Organ Dysfunction in Pediatric Severe Sepsis.A Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: The Optimizing Antibiotic Strategies in Sepsis (OASIS) Study.The American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: Executive Summary.The Epidemiology of Hospital Death Following Pediatric Severe Sepsis: When, Why, and How Children With Sepsis Die.Improving Recognition of Pediatric Severe Sepsis in the Emergency Department: Contributions of a Vital Sign-Based Electronic Alert and Bedside Clinician Identification.Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.Combining Prognostic and Predictive Enrichment Strategies to Identify Children With Septic Shock Responsive to Corticosteroids.A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.
P50
Q26829656-BCE67F62-674C-480C-A063-4866E02031FDQ30234906-4B224C84-52B4-4DEA-8D18-39F9D1251B6CQ33434503-2D33B1C7-DFA4-4F08-A563-0E65DCF22B20Q33587994-5AFBDFCE-3F47-4F97-9136-0992E2E0D77DQ33738328-5C13BF20-235B-4185-B516-5A60B87B0A01Q34204440-9E47919C-6746-4699-B233-A1E7CCC37E0BQ34424217-121BF7EB-9217-4CF4-8236-8F6DBDE30E45Q34434989-B8EE3D37-D7E5-4330-A9F9-C8CA7D0144B3Q34574858-96D63032-5543-410E-AD31-41933FB0F3F0Q34587242-8AC81D83-6E91-4D82-AACB-EA26EC5EC094Q35120147-2754DD0F-BDB9-483E-A050-BA92CAE299B0Q35123692-A6119B16-889B-4217-892B-DC705A2DF214Q35153451-9347E7CC-5DCB-4C9F-8A46-BA90991576F8Q35530413-0945322B-F9DF-4121-A6C9-C5DC4944594DQ35990696-3708B2CE-7377-4734-99A4-EF9A968779EDQ36067275-B65CB427-FAA8-4AEE-9BA8-11011AAECD7BQ36070766-CB0BD54F-E9DE-4170-BA38-804DAC6491F9Q36165065-1614301F-8559-447E-8BA0-18C9BFC18136Q36264836-6E7E06C9-4AFD-4203-8371-C7A8EC3911FCQ36341842-FCF8571C-E23F-49AF-A5E4-CB672A348FE1Q36437648-2237E1C1-F594-4DE1-AAE4-F48F27ACFDB7Q37143658-10491BAA-1FD2-4052-A045-D8D6A4EFCEA5Q37529311-C5E03E60-40AC-4613-BFB5-A8B409B86B48Q38766827-BC80B159-40F9-44F3-B1A9-A0233DC71184Q38783264-7F999D13-CDD0-4C39-BA29-EE947D0EFC06Q39034299-D2C79C98-D55A-4439-A872-529CE1C6FDB8Q39036127-4C5B265A-CF60-4026-8A7A-E9304CC437F7Q39385892-DE397197-AF44-4ED9-A0A6-18A85256ECADQ39500397-B5E0FBD1-1AD3-4263-A96A-2170484DD220Q39562884-21C23DE1-FBDC-42C3-A395-0FFEE50A22C1Q39793018-6CD999EC-41C5-4BCE-94AE-74FCD47B651DQ40116488-E78C4450-05C8-45F6-AFCF-660BA94EADECQ40183960-59513418-A556-4701-BE65-322A6F06DB13Q40184544-A5520F29-94AB-46B9-AE73-3676B30A3FD1Q40247636-28015C2F-DF5E-450D-97A3-F86151CBCE6BQ40285651-13E38227-8C0E-4B06-9800-A6AFA6096261Q40609257-342CF9BE-2802-4F98-8F50-1D38C9BDD101Q40642645-7115A83D-C134-4D80-A73C-8ACD10BA8AEDQ40675926-175E2348-BDFF-4C1C-AE50-999A1C857302Q40681392-C5F2385D-D699-48F0-85E4-5E7E5DAADB34
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Julie Fitzgerald
@ast
Julie Fitzgerald
@en
Julie Fitzgerald
@es
Julie Fitzgerald
@nl
Julie Fitzgerald
@sl
type
label
Julie Fitzgerald
@ast
Julie Fitzgerald
@en
Julie Fitzgerald
@es
Julie Fitzgerald
@nl
Julie Fitzgerald
@sl
prefLabel
Julie Fitzgerald
@ast
Julie Fitzgerald
@en
Julie Fitzgerald
@es
Julie Fitzgerald
@nl
Julie Fitzgerald
@sl
P106
P1153
7402450965
P21
P31
P496
0000-0001-9936-9569